Sinus Dilation Devices Market to Surpass US$ 5.7 Billion by 2026


Posted May 21, 2019 by VedantR

Sinus dilation devices play a major role in modern healthcare, allowing the sinus openings to expand during nasal sinusitis and are preferred over antibiotics, decongestants, or steroids, as it provides long-lasting and immediate results.

 
Sinusitis is an inflammation of sinus, which causes nose blockage and avoids mucus drainage. Sinus dilation devices are used in patients with nose drainage issues related to nasal sinusitis or sinuses to expand the sinus openings. Different types of Sinus Dilation Devices can be utilized for patients according to the need of the treatment, which includes balloon sinuplasty systems, rhinoscopes, sinus stents, and functional endoscopic sinus surgery (FESS), and instruments set for sinuses or sinusitis. During balloon sinus dilation procedure, doctor reshapes the patient's sinus pathway with inflated balloons to open the blocked sinus or nasal pathway.
Factors driving the sinus dilation devices market are increasing prevalence of chronic sinusitis, growing preference for minimally invasive surgeries, and favorable reimbursement scenario of surgical treatments for hospital outpatient department. According to the Centers for Disease Control and Prevention (CDC), in 2016, around 26.7 million adults in the U.S. were diagnosed with chronic sinusitis.

Get a Request Sample of Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/2451

According to National Center for Biotechnology Information (NCBI), over 600,000 ambulatory sinonasal cases are performed each year in the U.S. Centers for Medicare Services (CMS) reassigned the nasal/sinus endoscopy codes, for instance, sphenoid balloon dilation (31297) and maxillary FESS procedures (31267) were reassigned to higher paying Ambulatory Payment Classifications (APCs). This resulted in a significant payment increase of 52.6%, which increased reimbursed cost of both the endoscopic sinus surgeries from US$ 2,009 in 2015 to US$ 3,066 in 2016.

According to the Centers for Disease Control and Prevention (CDC), in 2016, around 26.7 million adults in the U.S. were diagnosed with chronic sinusitis. Chronic sinusitis affects 146 per 1000 people in the U.S., while in Canada the estimated prevalence of diagnosed chronic sinusitis is around 2% to 2.5% of the population. Sinusitis results in over 18-22 million physician visits per year in the U.S. The socioeconomic burden is valued at US$ 3.4-5 billion annually, for the treatment of this chronic sinusitis.

Furthermore, according to the study published in the U.S. National Library of Medicine, up to 64% of the patients suffering from acquired immune deficiency syndrome (AIDS) have possibility to develop chronic sinusitis in their course of life.

For More Information On This Report, Please Visit @ https://www.coherentmarketinsights.com/market-insight/sinus-dilation-devices-market-2451

A study conducted by American Journal of Rhinology & Allergy in 2014, suggested that the complication rate for balloon sinuoplasty (BSP) was 5.26% and it was 7.35% for conventional functional endoscopic sinus surgery (FESS). Major complications associated with the endoscopic surgeries are due to balloon sinuplasty

Key players operating in the global sinus dilation devices market include, Entellus Medical, Inc., Smith & Nephew Plc., Acclarent, Inc., B. Braun Melsungen AG, Medtronic Plc, Olympus Corporation, SinuSys Corporation, InnAccel Technologies, Intersect ENT, Inc.
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By Mr.Shah
Phone 12067016702
Business Address 1001 4th Ave,
#3200
Country United States
Categories Business , Health , Medical
Tags sinus dilation devices market outlook , sinus dilation devices market size , sinus dilation devices market
Last Updated May 21, 2019